Business Development

Developing and innovating together

Image
Business Development 2021@ Pierre-fabre
Our group has been built on the strength of our long-lasting partnerships. 
We are convinced that the synergies created from combining talents and expertise are the key to accelerating innovation.
The best success stories are those that are written together.

A Model for Long-Term Partnerships

Pierre Fabre has grown to be a major international player in pharmaceuticals, whilst maintaining a human dimension to our activities. This allows us to adapt quickly and act with creativity and agility to bring innovative projects with our partners to a successful conclusion, and to provide optimal access to markets and targeted promotion of differentiated therapeutic products. To embark on a collaboration with Pierre Fabre is to partner with a company who benefits from strong governance and stability due to its unique shareholder structure, thus guaranteeing a long-term strategic vision. Our corporate alliances benefit fully from our expertise, allowing us to execute efficiently the agreements put into place with our partners.
At Pierre Fabre we are committed to building partnerships which will develop and grow over time. An Alliance Management team, in charge of current partnerships, ensures that the value created through the collaboration is nurtured and optimized at all times, both at project and corporate level.

What are we looking for?

Oncology:

Oncology is a priority field of activity for Pierre Fabre, with more than 40 years of experience in the research, development and marketing of innovative products.
Within our Business Development activities, we are principally focused on innovative products ranging from the pre-clinical stage through to the late stages of development, including;

  • Innovative products targeting subpopulations of patients with solid tumors such as skin cancers, including melanoma; gastrointestinal, lung and gynaecological cancers affecting women.
  • Targeted therapeutics focused on oncogenes, key signaling pathways in the tumorigenesis process and tumoral resistance
  • Therapies targeting the tumour micro environment, notably immune-suppressive mechanisms.

We are particularly interested in different therapeutic classes including small molecules, monoclonal antibodies and antibody drug conjugates.

 

Prescription Medicines:

Prescription medicines are consolidated within our Pharmaceutical Care division and represent nearly 70% of the revenues of our Medical Care Business Unit. Our product portfolio is primarily focused on urology, gynecology, and rheumatology drugs. These therapeutic areas are our priority for new acquisitions or license agreements. A significant number of products in our Pharmaceutical Care portfolio originate from licensing agreements, through which our partners benefit from Pierre Fabre’s extensive expertise in marketing, regulatory affairs and market access.

Our interest is focused on medicinal products that have already received marketing authorization, or which are near to launch, including promotional agreements primarily in Europe, as well as in other key geographic areas (Africa, Asia and the Middle East).


We offer you the opportunity to launch and maximize the potential of your products through flexible partnerships adapted to your needs, providing patients with effective therapeutic solutions.

 

Dermatology:

Pierre Fabre Dermatology is one of the main players in the field of medical dermatology. We have a particular interest in the following priority therapeutic areas;
-onco-dermatology (basal cell carcinoma, squamous cell carcinoma, actinic keratosis, cutaneous lymphoma, supportive treatments for oncology therapies)
-rare dermatological diseases (genetic diseases, autoimmune and autoinflammatory diseases) 
-pediatric dermatology (atopic dermatitis, hemangiomas, warts, molluscum contagiosum…).

 

Consumer Health Care:

Pierre Fabre’s know-how and reputation has also been built on providing premium brands that provide quality health and personal care products, in particular Naturactive and Pierre Fabre Oral Care. We are interested in new product opportunities in this area including;

Natural health products: phytotherapy, aromatherapy and dietary supplements with organic certification.
Oral care products: innovative products ranging from treatment of dental pathologies through to oral hygiene products.

 

Dermo-Cosmetics:

Pierre Fabre was a pioneer in the development of the dermo-cosmetics concept. 
Today we are one of the world leaders in this market. Our portfolio includes internationally renowned brands: Eau Thermale Avène, Ducray, Klorane, A-Derma, René Furterer...


Our priority is to acquire rights or enter into collaborations for innovative active ingredients, formulation technologies, packaging, innovative electronic devices and turnkey products; with a particular emphasis on natural and environmentally responsible products.

We are also interested in acquiring or investing in innovative companies in this area, with differentiated business models or products.
 

Want to go further? Contact our Business Development team

Head of Corporate Business Development
Maurice CHELLI Head of Corporate Business Development CONTACT HIM ON LINKEDIN
Mergers and Acquisitions & Consumer
Damien BAUR  Mergers and Acquisitions & Consumer CONTACT HIM ON LINKEDIN
Claire KANONY TRUC Mergers and Acquisitions & Consumer CONTACT HER ON LINKEDIN
Teresa GALLARDO DOLS Natural Products & Oral Care CONTACT HER ON LINKEDIN
Medical Care
Julien DESGRIPPES Oncology & Dermatology     contact HIM ON linkedin
Isabelle RAULY Dermatology (Late Stage Products) contact HER ON linkedin
Valérie MAGNE Oncology (Late stage Products) contact HER
External Innovation & Science
Abderrahim MAHFOUDI  Oncology (Early Stage) & Open Innovation contact HIM ON linkedin
Christine KLINGUER HAMOUR Oncology (Early Stage Biologics) contact HER ON linkedin
Philippe SCHMITT Oncology (Early Stage Small Molecules)   Contact HIM ON linkedin
Alliance Managment
Frédéric BONFILS Alliance Managment CONTACT HIM ON LINKEDIN

 

Our process for evaluating and implementing external opportunities combines proactive discussion with rigor

 

 

Image
Schema Business Development

Would you like to meet us?

Discover all the congresses where we will be present in the coming months

 

 

2022 Congress country
January     JP MORGAN Virtual
January JPM WEEK Virtual
March ACCELERATING INNOVATION IN WOMEN HEALTH Virtual
March NATEXPO - NATURAL PRODUCTS EXPO - WEST USA
March PIERRE FABRE BIOPHARMA VIRTUAL EVENT Virtual
March AAD USA
March BIO EUROPE SPRING Virtual
April MARCUS EVANS, Strategic Alliance Management for Pharma * NETHERLANDS
April AACR * USA
May ESMO BREAST GERMANY
May CHINABIO PARTNERING FORUM CHINA
May VITAFOODS SWITZERLAND
May ASGCT (American Society of Gene and Cell Therapy) USA
May RARE DISEASE INNOVATION AND PARTNERING SUMMIT USA
May ADVANCED THERAPIES UK
June ASCO * USA
June ASCO * USA
June BIO INT'L CONVENTION - USA USA
June ESMO GI (European Society For Medical Oncology) SPAIN
September ESMO FRANCE
September ASAP - Biopharma Conference - USA USA
September EADV ITALIA
September NATEXPO FRANCE
September IPLS (International Pharma Licensing Symposium) UK
Octobrer PHYT'AROM FRANCE
Octobrer BIO EUROPE Automne GERMANY
Octobrer DTX EUROPE UK
November WORLD ORPHAN DRUG CONGRESS  SPAIN
November CPHI Worldwide GERMANY
November JEFFERIES Healthcare Conference UK
November STRATEGIC ALLIANCE MANAGEMENT CONGRESS EUROPE * EUROPE
November SITC USA
November EBCC (European Breast Cancer Conference) SPAIN
December SABCS San Antonio Breast Cancer Symposium USA
December AROMADAYS NETHERLANDS
December ASH  USA